Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
May 22 2023 - 11:00AM
Specialty cancer diagnostics company Precipio, Inc. leveraged
its proprietary HemeScreen technology as part of the diagnostic
process to monitor a patient with a history of Chronic Myeloid
Leukemia (CML) and p210 isoform expression which allowed the lab to
uncover an additional oncogene isoform expression (p190).
While many labs only monitor previously detected
mutations for analysis of Minimal Residual Disease Status (MRD) for
CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled
Precipio’s clinical lab to detect a co-expression of both p190 and
p210 isoforms in this patient leading to more informed care
decisions for the treating physician.
Changes in isoform expression may happen over
time during the course of treatment. The HemeScreen BCR-ABL1 panel
simultaneously detects 4 isoforms including p190, p203, p210, and
p230 to provide a comprehensive, easy to use assay for its clinical
lab.
“This case is a perfect example of why we
developed the HemeScreen platform with a panel-based approach to
ensure we are providing doctors a more comprehensive picture of
their patients’ molecular status”, said Ilan Danieli CEO. “We, and
our customers, continue to see the benefits of using the HemeScreen
BCR-ABL1 panel both in lab operations efficiencies and results such
as these that enable doctors to make more informed care
decisions.”
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide, as well as proprietary products that serve
laboratories worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment, Precipio offers a new standard of diagnostic
accuracy enabling the highest level of patient care. For more
information, please visit www.precipiodx.com.
Please follow us on LinkedIn, Twitter
@PrecipioDx and on Facebook.
Inquiries:
Contact@precipiodx.com
+1-203-787-7888
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Jul 2023 to Jul 2024